• Corheart 6 LVAS Study

  NCT05876000

  RecruitingInterventionalNot ApplicableUpdated Jan 8, 2026
• Corheart 6 LVAS LTFU

  NCT05928273

  CompletedInterventionalNot ApplicableUpdated Jul 3, 2023
• Corheart 6 LVAS Long-term Follow-up Study

  NCT06267612

  Not yet recruitingInterventionalNot ApplicableUpdated Feb 20, 2024
• Corheart 6 LVAS Clinical Investigation

  NCT07700810

  Not yet recruitingInterventionalNot ApplicableUpdated Jul 17, 2026
• Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial

  NCT05353816

  Active, not recruitingInterventionalNot ApplicableUpdated Feb 2, 2026
• Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure

  NCT00751972

  CompletedInterventionalNot ApplicableUpdated May 30, 2018

ClinicalTrials.gov ID

NCT07094919

Lead Sponsor

China National Center for Cardiovascular DiseasesOTHER_GOV

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

160Estimated

Last Update Posted

Jul 31, 2025Actual

Start Date

Dec 12, 2021Actual

Primary Completion Date

Sep 30, 2027Estimated

Completion Date

Sep 30, 2030Estimated

Official Title

An Cohort Study of Corheart 6 Left Ventricular Assist System for the Treatment of Patients With Advanced Left Heart Failure

Brief Summary

This study aims to evaluate the long-term effectiveness and safety of Corheart 6 left ventricular assist system as a treatment for patients with advanced left heart failure. The patients who have received the Corheart 6 treatment since October 2021, or who are planned to received it, will be enrolled until the target sample size meets statistical requirements.

Data collected will include survival status, cardiac function status, quality of life, laboratory parameters and adverse events. The primary endpoint are the composite of survival at 6 months and, separately, at 24 months, defined as survival with device support, bridge to heart transplant and device explantation due to cardiac recovery, without disabling stroke (mRS > 3) or device replacement. Data collection will adhere to the follow-up schedule specified in the protocol.

• Heart Failure

• Corheart 6 left ventricular assist system

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Age ≥ 18 years.

• Subject who have undergone Corheart 6 implantation on or after October 1, 2021.

• Body Surface Area (BSA) > 1.0 m2.

• Women of childbearing potential must use agree to use a effective method of contraception for the duration of the study.

• Diagnosis of NYHA Class IV heart failure, refractory to optimal guideline-directed medical therapy (GDMT) (e.g., ACE inhibitors, β-blockers, and diuretics).

• Left Ventricular Ejection Fraction (LVEF) < 30%, with at least one of the following conditions:

  1. Dependence on an intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO), or other short-term mechanical circulatory support with an inability to be weaned.
  2. Dependence on continuous intravenous inotropic support.
  3. Meets the diagnostic criteria for cardiogenic shock: blood pressure < 90/60 mmHg, cardiac index < 2.0, pulmonary capillary wedge pressure > 18 mmHg

• Subject or their legally authorized representative agrees to participate in the study and signs the informed consent form.

Exclusion Criteria:

• Heart failure caused by unresolved thyroid disease, hypertrophic obstructive cardiomyopathy, pericardial disease, or related conditions.
• Presence of active, uncontrolled infection confirmed through clinical symptoms and laboratory tests.
• Based on the investigator's judgment, presence of technical difficulties that would lead to unacceptable surgical risk.
• Subject is intolerant to anticoagulation or antiplatelet therapy, or cannot receive other perioperative and postoperative treatments deemed necessary by the investigator based on the patient's health condition.
• Require biventricular assist device support.
• Pregnancy.
• Presence of moderate to severe aortic regurgitation or a history of mechanical aortic valve implantation but refuse or is unable to converted to a bioprosthesis or oversewn at the time of LVAD implant.
• History of any organ transplant.
• Presence of unresolved thrombocytopenia or severe coagulopathy, such as disseminated intravascular coagulation (DIC).
• Preoperative total bilirubin (TBIL) > 3.0 mg/dL, serum creatinine (SCr) > 3.0 mg/dL, or requirement for dialysis within 48 hours prior to surgery.
• History of severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, or diagnosed primary pulmonary hypertension.
• Presence of pulmonary embolism within 3 weeks prior to enrollment.
• Pulmonary artery systolic pressure greater than 60 mmHg and meet at least one of the criteria which prove the pulmonary vessels is unresponsive to pharmacologic intervention: a. most recent pulmonary vascular resistance (PVR) ≥ 8 Woods; b. transpulmonary pressure > 20mmHg.
• History of confirmed, untreated abdominal aortic aneurysm (AAA) or thoracic aortic aneurysm (TAA) > 5 cm in diameter.
• Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration.
• Mental illness/disorder, irreversible cognitive dysfunction, or psychosocial issues that may prevent the patient from adhering to the study protocol and the management of the implanted left ventricular assist device, or any condition leading to brain death.
• Presence cancer or other diseases that could limit survival to less than 24 months.
• Participation in any other clinical investigation that is likely to confound study results or affect the study.
• Unforeseen circumstances that the investigator determines to be unsuitable for the study.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

China National Center for Cardiovascular DiseasesOTHER_GOV

qiangxianwang@163.com